News – Page 1150 – Endpoints News

Wait a second. J&J is back in the bidding for Actelion, elbowing Sanofi aside

9 years ago

Sumitomo Dainippon beefs up oncology pipeline with $780M Tolero buyout

9 years ago

Roche will have to wait on its big MS drug application; Pfizer ties up with BioInvent on new antibodies for cancer

9 years ago

Galapagos, AbbVie glimpse early progress in search of a cystic fibrosis triple to rival Vertex

9 years ago

Can Sanofi push a CVR on Actelion after the Lemtrada fiasco?

9 years ago

Is biopharma’s Midas man Vivek Ramaswamy building a new IPO vehicle with Dermavant deal?

9 years ago

Incyte antes up $200M — promises billions more — to launch a bispecific development deal with Merus

9 years ago

Merrimack shutters a failing PhII breast cancer study for MM-302

9 years ago

Allergan’s deal spree continues with $2.9B LifeCell buyout

9 years ago

Novartis adds opthalmology buyout in year-end deal spree; Tesaro gets a speedy FDA review for niraparib

9 years ago

Acadia shares skid as Nuplazid clears mid-stage hurdle for Alzheimer’s psychosis, but skeptics pounce

9 years ago

Akebia forges $1B US pact with Otsuka on lead drug for CKD, shares spike

9 years ago

Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal

9 years ago

Watch out Gilead, GSK’s ViiV is steaming ahead with promising late-stage data on a two-drug HIV therapy

9 years ago

Microcap Conatus teams up with pharma giant Novartis on NASH drug, shares rocket up

9 years ago

Surprise! Biogen goes with commercial chief Vounatsos in replacing CEO Scangos

9 years ago

After an R&D odyssey filled with setbacks, Clovis wins an FDA OK for rucaparib

9 years ago

Ionis reports a positive PhIII for volanesorsen in rare metabolic disorders

9 years ago

Sanger spinout gets $10M, tackles the microbiome frontier; Adaptimmune and Bellicum partner T cell tech

9 years ago

Yes, Loxo is still planning on seeking an accelerated OK, in case you had forgotten

9 years ago

Shanghai biotech upstart raises $50M, bags antibody discovery group and ramps up Boston unit

9 years ago

Innate Pharma woos Mondher Mahjoubi away from AstraZeneca’s cancer research ops to take the helm

9 years ago

Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade

9 years ago

Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic

9 years ago

First page Previous page 1147 1148 114911501151 1152 1153 Next page Last page